Scenario:A pharmaceutical sales representative distributes a…
Scenario:A pharmaceutical sales representative distributes a brochure to clinical specialists claiming that a newly approved drug is “the ultimate and safest breakthrough therapy for rheumatoid arthritis,” but fails to mention a prominent Boxed Warning regarding severe, opportunistic infections that is featured on the FDA-approved professional labeling. Question:Which FDA division is responsible for addressing this promotional violation, and what is the typical regulatory action taken?
Read Details